$91.97
1.62% day before yesterday
NYSE, Jun 06, 10:10 pm CET
ISIN
US7140461093
Symbol
RVTY

PerkinElmer Stock price

$91.97
+1.55 1.71% 1M
-24.49 21.03% 6M
-19.64 17.60% YTD
-19.05 17.16% 1Y
-13.34 12.67% 5Y
+39.92 76.70% 10Y
+72.66 376.28% 20Y
NYSE, Closing price Fri, Jun 06 2025
+1.47 1.62%
ISIN
US7140461093
Symbol
RVTY
Sector

Key metrics

Market capitalization $10.84b
Enterprise Value $12.87b
P/E (TTM) P/E ratio 38.64
EV/FCF (TTM) EV/FCF 24.56
EV/Sales (TTM) EV/Sales 4.65
P/S ratio (TTM) P/S ratio 3.91
P/B ratio (TTM) P/B ratio 1.44
Dividend yield 0.30%
Last dividend (FY24) $0.28
Revenue growth (TTM) Revenue growth 1.62%
Revenue (TTM) Revenue $2.77b
EBIT (operating result TTM) EBIT $401.53m
Free Cash Flow (TTM) Free Cash Flow $524.11m
Cash position $1.14b
EPS (TTM) EPS $2.38
P/E forward 37.54
P/S forward 3.81
EV/Sales forward 4.52
Short interest 6.31%
Show more

Is PerkinElmer a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

PerkinElmer Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a PerkinElmer forecast:

12x Buy
60%
7x Hold
35%
1x Sell
5%

Analyst Opinions

20 Analysts have issued a PerkinElmer forecast:

Buy
60%
Hold
35%
Sell
5%

Financial data from PerkinElmer

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,770 2,770
2% 2%
100%
- Direct Costs 1,212 1,212
0% 0%
44%
1,558 1,558
3% 3%
56%
- Selling and Administrative Expenses 961 961
4% 4%
35%
- Research and Development Expense 200 200
5% 5%
7%
819 819
2% 2%
30%
- Depreciation and Amortization 417 417
3% 3%
15%
EBIT (Operating Income) EBIT 402 402
9% 9%
14%
Net Profit 287 287
92% 92%
10%

In millions USD.

Don't miss a Thing! We will send you all news about PerkinElmer directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PerkinElmer Stock News

Neutral
Business Wire
6 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference standards have ...
Neutral
Business Wire
20 days ago
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays (ChLIA). The IDS i20 platform is a CE marked and FDA listed device that allows laboratories to consolidate multiple specialty tests on a unique single instrument with greater reage...
Negative
Seeking Alpha
30 days ago
Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the company maintained full-year guidance. While I rate Revvity a buy, it faces some structural challenges longer-term.
More PerkinElmer News

Company Profile

PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment comprises of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937 and is headquartered in Waltham, MA.

Head office United States
CEO Prahlad Singh
Employees 11,000
Founded 1937
Website www.revvity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today